Modality
Fusion Protein
MOA
ALKi
Target
CD20
Pathway
Apoptosis
RAWMHemophilia A
Development Pipeline
Preclinical
Nov 2021
→ Mar 2028
PreclinicalCurrent
NCT07792478
2,092 pts·WM
2022-01→2028-03·Terminated
NCT08583522
2,416 pts·WM
2021-11→2026-11·Not yet recruiting
4,508 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-11-238mo awayInterim· WM
2028-03-252.0y awayInterim· WM
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Preclinical
Not yet…
Preclinical
Termina…
Catalysts
Interim
2026-11-23 · 8mo away
WM
Interim
2028-03-25 · 2.0y away
WM
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07792478 | Preclinical | WM | Terminated | 2092 | UPCR |
| NCT08583522 | Preclinical | WM | Not yet recr... | 2416 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA |